Abstract
Background Assessment of newborn screening using whole genome sequencing (WGS) presents considerable challenges for policy advisors, not least given the logistics of simultaneously evaluating the evidence for 200 rare genetic conditions. The ‘genotype first’ approach has the potential for harms, and benefits are uncertain.
Objective To assess different approaches to evaluating WGS for newborn screening to inform the development of a robust method for informing policy decisions.
Methods We undertook ‘traditional’ reviews of five conditions using standard systematic review methods (considering gene penetrance, expressivity, and prevalence, the accuracy and effectiveness of WGS, and effect of earlier treatment) (search inception to November 2023), evaluated the NIH Clinical Genome Resource (ClinGen) for evidence on the five conditions, reviewed genomic studies of paediatric screening cohorts reporting penetrance for pathogenic variants (search inception to February 2024) and undertook a methodological review of economic evaluations of WGS/ whole exome sequencing (WES) (search inception to January 2024). We explored public views on evaluating WGS.
Data sources MEDLINE (Ovid), Embase (Ovid), Web of Science, Science Citation Index (via Clarivate), the Cochrane Library (via Wiley), CEA registry and Econlit.
Actionability reports and scores were downloaded from the ClinGen website on 30th April 2024.
Results The traditional review approach identified 221 studies that either reported on the genetic spectrum of individuals with the five conditions or provided limited evidence about the benefits of earlier treatment. No evidence about penetrance and expressivity or the accuracy or effectiveness of WGS in newborns was identified. ClinGen reviews were available for four of the five conditions. The ClinGen ‘actionability’ ratings for all four conditions disagreed with the findings of our traditional reviews. Our review of 14 genomic studies of newborn screening cohorts found insufficient information to allow individual highly penetrant pathogenic variants for any condition to be identified for consideration in a screening programme. None of the 86 economic evaluations of WGS or WES were set in a screening context. Some micro-costing studies are available that could help understand the resource use and costs associated with WGS. Following a series of PPI meetings, attendees appreciated the uncertainties of WGS and suggested that a wider stakeholder perspective was needed to inform policy decisions.
Limitations Although we only examined five conditions in depth, the consistency in lack of data suggests our conclusions are robust.
Conclusions The traditional systematic review approach for evaluating WGS of newborns identified a paucity of high-quality evidence. Extending the review to all 200 conditions is not feasible and is unlikely to yield the level of evidence required by policy advisors. The use of existing genome resources and review of genomic studies of newborn screening cohorts were not found to be viable alternatives. The cost-effectiveness of WGS in a newborn screening context is unknown.
Future work Large-scale collaborative research is required to evaluate the short- and long-term harms, benefits and economic implications of WGS for screening newborns. We propose a staged approach to evaluation considering only conditions with pathogenic variants with very high penetrance to minimise harm from overdiagnosis.
Study registration The protocol for this study is registered on PROSPERO: CRD42023475529
Funding details This study/project is funded by the NIHR Evidence Synthesis Programme (ESG_HTA_NIHR159928). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Competing Interest Statement
Primary conflicts of interest: KF, JD, BS, CC, IK, KS, SC, AO, ND, RC, FB, FB, YT and STP received funding from the National Institute for Health and Care Research Evidence Synthesis Programme (ESG_HTA_NIHR1599280) to undertake this work. JD received funding from the Birmingham Biomedical Research Centre (BRC). FB received funding from Genomics England Limited for a process and impact evaluation. BS is a member of the UK NSC. CV is a Principal Evidence Review Manager of the UK NSC. JRB, DE and GS are clinical advisors to the UK NSC. AM is the Director of Programmes for the UK NSC. JRB is President of the International Society of Neonatal Screening. ZM is co-chair of the Scottish Clinical Genomics Forum and a committee member of the Clinical Genetics Society, the Scottish Strategic Network for genomic medicine, the NHSE rare disease test evaluation working group and board member of the Royal Colleges Genomics Advisory Board. FB is a member of the UK NSC Foetal, Maternal and Child Health Reference Group, the Bloodspot Task group and the Spinal Muscular Atrophy In Service Evaluation Partnership Board. STP is a member of the UK NSC AI task group, and chair of the UK NSC Research Methodology Group. SM has nothing to declare.
Clinical Protocols
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=475529
Funding Statement
This study/project is funded by the NIHR Evidence Synthesis Programme (ESG_HTA_NIHR159928). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No new data have been created in the preparation of this article and therefore there is nothing available for access and further sharing. All queries should be submitted to the corresponding author.
Glossary
- Biallelic
- Referring to both alleles of a gene
- ClinGen
- Resource funded by the National Institutes of Health that centralises information about the clinical relevance of genes and variants
- Clinical actionability
- Level of evidence about pathogenicity, penetrance and expressivity of a genetic variant and the extent to which interventions can be used to mitigate the effect of the disease
- Digenic
- Referring to two genes
- Dosage sensitivity
- Refers to the impact of changes in gene dosage (the number of copies of a gene) on an organism’s phenotype
- Exon
- Coding sequence of DNA within a gene that is retained during the RNA splicing process before translation into protein
- Expressivity
- Degree to which a trait/condition is expressed in individuals with a particular genetic variant
- Founder effect
- Phenomenon where a small group of individuals establishes a new population, leading to reduced genetic diversity compared to the original population. The presence of an allele at an unusually high frequency in an isolated population.
- Gene-disease validity
- Level of evidence supporting the association between a specific gene and a disease/phenotype
- Gene dosage
- Number of copies of a particular gene present in a cell/organism and hence related to the amount of gene product
- Generation Study
- UK study run by Genomics England in partnership with the NHS to sequence the genome of newborn babies in the UK and screen for 200 rare genetic conditions
- Genomics England
- Company set up by the UK Department of Health and Social care to run the 100,000 Genomes Project. It is now overseeing the Generation Study
- Germline variant
- A variant within germ cells that can be passed on to offspring
- Intron
- Non-coding sequence of DNA within a gene that is removed during the RNA splicing process before translation into protein
- Monoallelic
- Referring to a single allele of a gene
- Mosaicism
- Refers to the presence of multiple populations of cells with different genotypes in a single individual due to variants occurring in some cells during development
- Penetrance
- Proportion of individuals with a given genetic variant who display the traits/condition
- Private variants
- Gene variants that is specific to an individual or family and not commonly found in the wider population
- Proband
- Individual in a family who is first identified as having a particular genetic condition
- Sporadic variants
- Gene variants that arise spontaneously in an individual without being inherited from a parent
- Vairant annotation
- Variant annotation is the process of assigning functional information to an DNA alteration such as the effect on protein structure.
- Variant
- Change/alteration in the DNA sequence that may affect how a gene functions. Variants can be benign, pathogenic or of unknown significance
- Variant interpretation
- Variant interpretation is the process of drawing direct links between individual variants and a disease phenotype for decisions on reporting. This requires expert interpretation and literature review and Consideration of context (other genetic factors, environmental factors, ancestry, sex, type of phenotype (symptomatic disease) under Consideration). Guidelines for variant interpretation for instance by ACMG are available to standardise interpretation of variant pathogenicity and categorisation into pathogenic, likely pathogenic, uncertain, likely benign and benign.
- Variant of unknown significance
- Variant for which there is insufficient information to determine its impact on disease risk/health.
- Variant prioritisation
- Variant prioritisation is the process of filtering variants identified through sequencing using bioinformatic tools to identify variants most likely linked to a disease phenotype. More advanced tools include information on predictions about effect on protein structure, conservation (conserved sequences across all vertebrates), constraint (gene regions intolerant to loss of function variants), variant frequency, mode of inheritance and gene-disease associations.
- Pathogenicity (variant pathogenicity)
- A variant is classified as pathogenic if evidence confirms that it causes disease based on variant interpretation. Information for variant interpretation and variant prioritisation is generally based on family, clinical and case control studies which are enriched for etiological co-factors, which means penetrance in these cohorts is overestimated. Pathogenicity annotations used in the screening context have got implications for specificity as ‘known’ pathogenic variants have lower penetrance in population-based studies. Degree to which a variant impacts the function of a gene. >99% probability of pathogenicity defined as pathogenic variant and 90%–99% probability of pathogenicity defined as likely pathogenic variant.
- Whole exome sequencing
- Technique for sequencing all the protein-coding regions of genes (exons) in a genome
- Whole genome sequencing
- Technique for sequencing the entire DNA (genome) of an individual
- AABR
- Automated Auditory Brainstem Response
- ACMG
- American College of Medical Genetics and Genomics
- CEA
- Cost-Effectiveness Analysis
- ClinGen
- Clinical Genome Resource
- ClinVar
- Clinical Variation
- CNV
- Copy Number Variant
- CRD
- Centre For Reviews And Dissemination
- DBS
- Dried Blood Spot
- DEIB
- Diversity, Equity, Inclusion, And Belonging
- DNA
- Deoxyribonucleic Acid
- FAOD
- Fatty Acid Oxidation Disorders
- FH
- Family History
- fHLH
- Familial Hemophagocytic Lymphohistiocytosis
- G6PDD
- Glucose-6-phosphate dehydrogenase deficiency
- GEL
- Genomics England Limited
- GS
- Genomic Sequencing
- HLH
- Haemophagocytic Lymphohistiocytosis
- HPLC
- High Performance Liquid Chromatography
- hRB
- Heritable Retinoblastoma
- HSCT
- Hematopoietic Stem-Cell Transplantation
- HTA
- Health Technology Assessment
- ICoNS
- International Consortium On Newborn Sequencing
- ICU
- Intensive Care Unit
- IDD
- Intellectual Developmental Delay
- IEI
- Inborn Errors of Immunity
- IEM
- Inborn Errors of Metabolism
- IMD
- Inherited Metabolic Disease
- IQ
- Intelligence Quotient
- LRT
- Lysine Reduction Therapy
- MCADD
- Medium Chain Acyl-Coa Dehydrogenase Deficiency
- MeSH
- Medical Subject Headings
- MLPA
- Multiplex Ligation Dependent Probe Amplification
- mRNA
- Messenger Ribonucleic Acid
- NBS
- Newborn Bloodspot
- NGS
- Next Generation Sequencing
- NESTS
- NEwborn Screening with Targeted Sequencing
- NHS EED
- NHS Economic Evaluation Database
- NICU
- Neonatal Intensive Care Unit
- NSC
- National Screening Committee
- PCR
- Polymerase Chain Reaction
- PDE
- Pyridoxine Dependent Epilepsy
- Pi/D
- Oral phosphate and calcitriol (active vitamin D)
- PKU
- Phenylketonuria
- PPIE
- Patient And Public Involvement Engagement
- QALY
- Quality Adjusted Life Year
- QUIPS
- Quality In Prognostic Studies
- RCT
- Randomized Controlled Trial
- REC
- Retinoblastoma Variant Effect Class
- ROBIS
- Risk Of Bias In Systematic Reviews
- SD
- Standard Deviation
- SGP
- Scottish Genomes Partnership
- SMA
- Spinal Muscular Atrophy
- SNV
- Single Nucleotide Variant
- SSCP
- Single Strand Conformation Polymorphism
- VUS
- Variant of Unknown Significance
- WES
- Whole Exome Sequencing
- WGS
- Whole Genome Sequencing
- XLHR
- X-Linked Hypophosphataemic Rickets
